<?xml version="1.0" encoding="UTF-8"?>
<p id="p0260">Zikuan Leng et al. treated seven patients who are suffering from SARS-CoV-2 pneumonia with MSCs in Beijing You'an Hospital, China. They have evaluated the inflammation and immune-related parameters for 14 days after a single infusion of MSCs, where they found that all the patients recovered from all the symptoms without any adverse effects. Where MSCs inhibited the cytokine storm by upregulating the cytotoxic cells and suppressed the TNF-α levels. Thus, the intravenous administration of MSCs will be a safe and effective approach for treating severe SARS-CoV-2 pneumonia patients [
 <xref rid="bb0885" ref-type="bibr">177</xref>]. Various scientific groups are working on MSCs to treat SARS-CoV-2 and few of the studies are under the clinical trials (
 <xref rid="t0040" ref-type="table">Table 8</xref> ).
</p>
